Sai Life Expands Bidar API Capacity to 700 KL
ECONOMY & POLICY

Sai Life Expands Bidar API Capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO) focused on pharmaceutical innovation, has announced the completion of Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka.
Phase I of PB-11, inaugurated in December 2024, added 110 kilolitres (KL) of capacity. With the addition of approximately 91 KL in Phase II during Q1 FY26, PB-11 now totals nearly 200 KL of reactor volume—making it the single largest production block at the site. This expansion increases Sai Life’s total installed reactor capacity at the Bidar facility to around 700 KL.

Commenting on the development, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, stated, “This expansion is not just about capacity—it’s about scalability, reliability, and the ability to support clients as their needs evolve. We are enabling faster, more secure drug development by strengthening our commercial-scale API and intermediate manufacturing.”

PB-11 is a versatile block designed for the large-scale production of commercial products. Unit IV in Bidar serves as Sai Life’s core manufacturing hub, catering to highly regulated markets including the US, EU, and Japan.

Key features of the facility include:
  • 12 multipurpose production blocks totalling ~700 KL
  • Dedicated units for high-potency APIs (HPAPIs)
  • Advanced QC laboratories ensuring regulatory compliance
  • Capabilities such as lyophilisation, cryogenic and high-pressure reactions, and large-scale chromatography
The site has passed inspections by global regulatory bodies including the USFDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life’s manufacturing units had completed over 75 customer audits in the past three years—underscoring the company’s commitment to safety, quality, and regulatory excellence. 

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO) focused on pharmaceutical innovation, has announced the completion of Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka.Phase I of PB-11, inaugurated in December 2024, added 110 kilolitres (KL) of capacity. With the addition of approximately 91 KL in Phase II during Q1 FY26, PB-11 now totals nearly 200 KL of reactor volume—making it the single largest production block at the site. This expansion increases Sai Life’s total installed reactor capacity at the Bidar facility to around 700 KL.Commenting on the development, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, stated, “This expansion is not just about capacity—it’s about scalability, reliability, and the ability to support clients as their needs evolve. We are enabling faster, more secure drug development by strengthening our commercial-scale API and intermediate manufacturing.”PB-11 is a versatile block designed for the large-scale production of commercial products. Unit IV in Bidar serves as Sai Life’s core manufacturing hub, catering to highly regulated markets including the US, EU, and Japan.Key features of the facility include:12 multipurpose production blocks totalling ~700 KLDedicated units for high-potency APIs (HPAPIs)Advanced QC laboratories ensuring regulatory complianceCapabilities such as lyophilisation, cryogenic and high-pressure reactions, and large-scale chromatographyThe site has passed inspections by global regulatory bodies including the USFDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life’s manufacturing units had completed over 75 customer audits in the past three years—underscoring the company’s commitment to safety, quality, and regulatory excellence. 

Related Stories

Gold Stories

Next Story
Products

Koemmerling opens Navi Mumbai experience centre

Koemmerling, a brand of the profine Group, has expanded its presence in the Mumbai metropolitan region with the opening of a new experience centre in Navi Mumbai and launched its Allure S46 minimal sliding door system for the Indian market.Located in CBD Belapur, the facility was inaugurated by Peter Mrosik, Owner and CEO, profine Group, along with Farid Khan, Chairman and Managing Director, profine India, and Kamal Bajaj, CEO, profine India.The company said the new centre will showcase its portfolio of uPVC and aluminium window and door systems to architects, developers and homeowners.The ina..

Next Story
Products

India's waterproofing market nears Rs 150 bn milestone

India's waterproofing industry is approaching a market size of Rs 150 billion and is expected to surpass the $2 billion milestone, according to speakers at the 2nd India International Waterproofers Conference & Expo 2026 organised by the Waterproofers Association of India (WAI) in New Delhi.The two-day event brought together more than 20 speakers, 55 international delegates and 53 exhibition booths, with discussions focusing on climate-resilient construction, advanced waterproofing technologies and international collaboration.Inaugurating the event, Durga Shanker Mishra, former Secretary, ..

Next Story
Real Estate

Dilip Buildcon Q1 FY27 Revenue at Rs 23.78 billion

Dilip Buildcon Limited reported consolidated revenue from operations of Rs 2,378 crore in Q1 FY27, along with EBITDA of Rs 429 crore and profit after tax of Rs 128 crore.Consolidated EBITDA margin stood at 18.1%, improving from 17.1% in Q4 FY26. On a standalone basis, revenue from operations was Rs 1,930 crore, EBITDA stood at Rs 199 crore and PAT was Rs 39 crore, with an EBITDA margin of 10.3%.The company’s order book stood at Rs 27,691 crore as of 30 June 2026, compared with Rs 28,830 crore as of 31 March 2026. Roads and highways accounted for 17.1% of the order book, irrigation and water ..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement